Severe ulcerative colitis: Prospective study of parameters determining outcome

Journal of Gastroenterology and Hepatology (Australia)

Volumn 19, Issue 11, 2004, Pages 1247-1252

  Kumar, Sanjay ^a   Ghoshal, Uday C ^a   Aggarwal, Rakesh ^a   Saraswat, Vivek A ^a   Choudhuri, Gourdas ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Clinical severity scoring; Inflammatory bowel disease; Outcome prediction

Indexed keywords

ANTIBIOTIC AGENT; C REACTIVE PROTEIN; FIBRIN DEGRADATION PRODUCT; FIBRINOGEN; HEMOGLOBIN; HYDROCORTISONE; SERUM ALBUMIN;

ADULT; AGE; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CROHN DISEASE; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; FIBRINOGEN BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HUMAN; MALE; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL; PROTHROMBIN TIME; SCORING SYSTEM;

EID: 8344269408     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2004.03486.x     Document Type: Article

References (28)

1. Wright JP, O'Keefe EA, Cumming L, Jaskiewicz K. Olsalazine in maintenance of clinical remission in patients with ulcerative colitis. Dig. Dis. Sci. 1993; 38: 1837-42.
2. Misiewicz JJ, Lennard-Jones JE, Connell A, Baron JH, Avery Jones F. Controlled trial of sulphasalazine in maintenance therapy for ulcerative colitis. Lancet 1965; 1: 185-8.
3. Prakash A, Markham A. Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn's disease. Drugs 1999; 57: 383-408.
4. Chakravarty BJ. Predictors and the rate of medical treatment failure in ulcerative colitis. Am. J. Gastroenterol. 1993; 88: 852-5.
5. Truelove SG, Willoughby CP, Lee EG, Kettlewell MG. Further experience in the treatment of severe attacks of ulcerative colitis. Lancet 1978; 18: 1086-8.
6. Lennard-Jones JE, Ritchie JK, Hilder W, Spicer CC. Assessment of severity in colitis: a preliminary study. Gut 1975; 16: 579-84.
7. Oshitani N, Kitano A, Fukushima R et al. Predictive factors for the response of ulcerative colitis patients during the acute-phase treatment. Digestion 1990; 46: 107-13.
8. Jewell DP. Ulcerative colitis. In: Feldman M, Friedman LS, Sleisenger MH, eds. Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management, 7th edn. Philadelphia, PA: WB Saunders Company, 2002; 2039-67.
9. Jones HW, Grogono J, Hoare AM. Acute colitis in a district general hospital. Br. Med. J. 1987; 294: 683-4.
10. Truelove SC, Witts LJ. Cortisone in ulcerative colitis. Final report on a therapeutic trial. Br. Med. J. 1955; 2: 1041-8.
11. Lichtiger S, Present DH, Kornbluth A et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N. Engl. J. Med. 1994; 330: 1841-5.
12. Travis SP, Farrant JM, Ricketts C et al. Predicting outcome in severe ulcerative colitis. Gut 1996; 38: 905-10.
13. Linskens RK, van Bodegraven AA, Schoorl M, Baak JP, Tuynman HA, Bartels P. Predictive value of inflammatory and coagulation parameters in the course of severe ulcerative colitis. Dig. Dis. Sci. 2001; 46: 644-8.
14. Baron JH, Connell AM, Lennard-Jones JE. Variation between observers in describing mucosal appearances in proctocolitis. Br. Med. J. 1964; 1: 89-92.
15. Orii S, Chiba, T, Nakadate I et al. Pleuropericarditis and disseminated intravascular coagulation in ulcerative colitis. J. Clin. Gastroenterol. 2001; 32: 251-4.
16. Kornbluth A, Marion JF, Salomon P, Janowitz HD. How effective is current medical therapy for severe ulcerative and Crohn's colitis? An analytic review of selected trials. J. Clin. Gastroenterol. 1995; 20: 280-4.
17. Sandborn WJ, Tremaine WJ. Cyclosporine treatment of inflammatory bowel disease. Mayo Clin. Proc. 1992; 67: 981-90.
18. Lichtiger S, Present DH. Premliminary report: cyclosporine in treatment of severe active ulcerative colitis. Lancet 1990; 336: 16-19.
19. Picco MF, Bayless T. Prognostic considerations in idiopathic inflammatory bowel disease. In: Kirsner JB, ed. Inflammatory Bowel Disease, 5th edn. Philadelphia, PA: Williams & Wilkins, 2000; 765-80.
20. McInerney GT, Sauer WG, Baggenstoss AH et al. Fulminating ulcerative colitis with marked colonic dilatation. A clinico-pathologic study. Gastroenterology 1962; 42: 244-56.
21. Buckell NA, Lennard-Jones JE, Hernandez MA, Kohn J, Riches PG, Wadsworth J. Measurement of serum protein during attacks of ulcerative colitis as a guide to patient management. Gut 1979; 20: 22-7.
22. Yoshikane H, Sakakibara A, Ayakawa T et al. Disseminated intravascular coagulation in an ulcerative colitis case not associated with surgery. Hepatogastroenterology 2000; 47: 1608-10.
23. Handin RI. Disorders of hemostasis. In: Fauci AS, Braunwald E, Isselbacher JK et al., eds. Harrison's Principles of Internal Medicine. New York: McGraw-Hill, 1998; 730-43.
24. Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporine in ulcerative colitis: a five-year experience. Am. J. Gastroenterol. 1999; 94: 1587-92.
25. Marion JH, Present DH. Modern medical management of acute, severe ulcerative colitis. Eur. J. Gastroenterol. Hepatol. 1997; 9: 831-5.
26. Watts JM, De Dombal FT, Watkinson G, Goligher JC. Early course of ulcerative colitis. Gut 1966; 7: 16-31.
27. Kjeldsen J, Lassen JF, Brandslund I, Schaffalitzky de Muckadell OB. Markers of coagulation and fibrinolysis as measures of disease activity in inflammatory bowel disease. Scand. J. Gastroenterol. 1998; 33: 637-43.
28. Hendriksen C, Kreiner S, Binder V. Long-term prognosis in ulcerative colitis based on results from a regional patient group from the country of Copenhagen. Gut 1985; 26: 158-63.